RAPP

$27.08-0.38 (-1.38%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$27.08
Potential Upside
5%
Whystock Fair Value$28.43
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-17.26%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
36.37

Recent News

Simply Wall St.
Mar 21, 2026

How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China

In March 2026, Rapport Therapeutics granted Tenacia Biotechnology exclusive rights to develop and commercialize its clinical-stage epilepsy and bipolar candidate RAP-219 across Greater China, in a deal including a US$20 million upfront payment and up to approximately US$308 million in potential milestones plus tiered royalties. The agreement effectively turns Greater China into a major development hub for RAP-219, adding Phase 3 trial sites in China while allowing Rapport to retain rights in...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 16, 2026

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 16, 2026

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 16, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 18, 2026

We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. Indeed, Rapport Therapeutics...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.